DCM
ELEV

DAFNA Capital Management’s Elevation Oncology ELEV Stock Holding History

DAFNA Capital Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-450,000
Closed -$242K – 76
2023
Q4 		$242K Hold
450,000
– – 0.06% 69
2023
Q3 		$298K Hold
450,000
– – 0.09% 65
2023
Q2 		$684K Buy
+450,000
New +$1.19M 0.19% 58

Other funds holding ELEV

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DAFNA Capital Management's ELEV Position: Q1 2024 in Review

DAFNA Capital Management sold out of Elevation Oncology (ELEV) in Q1 2024, closing a stake of 450,000 shares — an estimated $242K sold.

DAFNA Capital Management first reported a position in ELEV in Q2 2023 and held it in 3 quarters. The position peaked at $684K in Q2 2023. 63 funds tracked by Wall St. Rank hold ELEV as of Q1 2024.

  • DAFNA Capital Management reported no remaining Elevation Oncology position as of Q1 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 450,000 Elevation Oncology shares in Q1 2024, an estimated $242K.
  • DAFNA Capital Management first reported a position in Elevation Oncology in Q2 2023 and held it in 3 quarters.
  • DAFNA Capital Management's Elevation Oncology position peaked at $684K in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.